Analyst Insights

Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights". Click on the premium insights link below to filter for just the premium content.



Signify Premium Insight: Intelerad Adds Insignia to its List of Acquisitions

Signify Premium Insights Subscription Required

16th September 2021 – Intelerad’s acquisition run continues, as Insignia Medical Systems is bought up by the Canadian vendor. The move will help Intelerad progress in the UK market, but, only if it can overcome the issues of integration.

Signify Premium Insight: DiA Deemed a Worthy Investment in $14m Funding Round

Signify Premium Insights Subscription Required

14th September 2021 – DiA Imaging Analysis recently secured $14m in its latest funding round. This Premium Insight considers what lessons can be learned from this, and other recent ultrasound AI investments.

Signify Premium Insight: ContextVision Weighs Digital Pathology Spin Off

Signify Premium Insights Subscription Required

9th September 2021 – ContextVision has revealed that it is considering spinning off its digital pathology unit. But, will the extra focus and flexibility this affords be worth the loss of synergy between the radiology and digital pathology businesses?

Signify Premium Insight: Nurturing Medical Imaging AI – The Russian Way

Signify Premium Insights Subscription Required

7th September 2021 – Russia’s medical imaging AI market is not as developed as those in some other countries, however, an innovative new project in Moscow could be set to help remedy this situation.

Signify Premium Insight: Hyperfine: Nascency to NASDAQ in One Fell Swoop

Signify Premium Insights Subscription Required

3rd September 2021 – Hyperfine, the first company to receive FDA approval for a portable MRI system, has announced it is going public. This Premium Insight assesses whether the MRI establishment should be worried about the young vendor, or whether in fact, Hyperfine is at greater risk?